

October 26, 2022

Simplist® Prefilled Syringe Supply Update

To Our Valued Customers,

We are pleased to announce key initiatives to support our Simplist prefilled syringe product portfolio. The enhancements are part of the ongoing investment in our U.S. manufacturing and supply chain infrastructure, and will play an integral role in preventing critical drug shortages in the future.

As one of the largest manufacturers of generic sterile injectable medicines in the United States, we play a critical role in ensuring that hospitals have the medicines they need to treat patients. Fresenius Kabi has a dedicated manufacturing facility for prefilled syringes, and we have begun implementing several initiatives to strengthen our supply reliability.

We have increased inventory levels across the Simplist portfolio, including stocking more than 6 months of supply for high-priority drugs. We have achieved extended 36-month stability dating for 9 syringes in our portfolio, including narcotics, enabling us to hold more inventory on hand without risking obsolescence.

To streamline manufacturing processes and to better meet demand for our most-ordered prefilled syringes, we are ceasing production of four Simplist presentations (see Table 1) and shifting production focus to build and maintain healthy stock levels of high-volume drugs to meet our customer demands.

We are proud to share that most of our Simplist prefilled syringes are formulated, filled, and packaged in the United States. We continue to invest in our state-of-the-art manufacturing and distribution centers in the U.S., consistent with our [More in America](#) commitment.

Our dedication to medication-use-safety includes providing nursing and pharmacy implementation support resources, pharmacy analytics tools, and innovative advanced +RFID labeling. For more information on our implementation services, including Optilytics™ storage solutions and to review a narcotic dose optimization case study, please visit our resources page on our [Simplist website](#) or contact your Fresenius Kabi sales representative.

We appreciate your ongoing partnership as we strive to provide better solutions to meet your most pressing needs for supply reliability and medication safety.

Sincerely,



Matt Kozak
Director, Marketing

October 26, 2022

Table 1 – Products with Discontinued Production and Fresenius Kabi Alternatives

Products with Discontinued Production			Fresenius Kabi Alternatives	
Product	Presentation	Unit of Sale NDC	Unit of Sale NDC	Presentation Form
Haloperidol Injection, USP	5 mg per 1 mL Prefilled Syringe	76045-737-10	63323-474-01	Vial
Ketorolac Tromethamine Injection, USP	15 mg per 1 mL Prefilled Syringe	76045-107-10	63323-161-01	Vial
Midazolam Injection, USP	5 mg per 1 mL Prefilled Syringe	76045-002-10	63323-412-25	Vial
Metoclopramide Injection, USP	10 mg per 2 mL Prefilled Syringe	76045-101-20	76045-213-20	RFID Prefilled Syringe*

*RFID-enabled Metoclopramide 10 mg per 2 mL prefilled syringe is expected to launch in 2023

###